La Jolla Pharmaceutical (LJPC) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-32.05M
Share-based compensation expense	6.96M
Issuance of Series C-1 Preferred Stock for services
Fair value of derivative liabilities upon issuance
Loss (gain) on adjustments to fair value of derivative liabilities
Prepaids and other current assets	-738K
Accounts payable and accrued expenses	-250K
Accrued payroll and related expenses	-295K
Net cash used for operating activities	-25.09M
Proceeds from issuance of derivative obligations
Net cash provided by financing activities	85K
Net (decrease) increase in cash and cash equivalents	-25.91M
Cash and cash equivalents at beginning of period	126.47M
Cash and cash equivalents at end of period	100.56M
Issuance of common stock at par value, offset by paid-in capital reduction
Conversion of preferred stock into common stock	0
Reclassification of preferred stock currently redeemable
Accrued dividends payable in preferred stock
Forfeiture of preferred stock dividends

Entities mentioned with LJPC

View All Entities